<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>62</patient-age><report-id>US-ELI_LILLY_AND_COMPANY-US201212008403</report-id><gender>female</gender><reactions><reaction>passed out due to high blood sugar</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>HUMALOG LISPRO</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LEVEMIR</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Type 2 diabetes mellitus</indication></indications><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734885_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151009</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-ELI_LILLY_AND_COMPANY-US201212008403</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-23</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-28</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-16</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-ELI_LILLY_AND_COMPANY-US201212008403</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>US-ELI_LILLY_AND_COMPANY-US201210001015</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reportertitle>Ms.</reportertitle>
			<reportergivename>Jewel</reportergivename>
			<reporterfamilyname>Printy</reporterfamilyname>
			<reporterstreet>805 West Kannal Avenue
Apartment 20</reporterstreet>
			<reportercity>Rensselaer</reportercity>
			<reporterstate>IN</reporterstate>
			<reporterpostcode>47978</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>Novo Nordisk</reporterfamilyname>
			<reporterstreet>100 College Road West</reporterstreet>
			<reportercity>Princeton</reportercity>
			<reporterstate>NJ</reporterstate>
			<reporterpostcode>08540</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JP</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19501106</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>passed out due to high blood sugar</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hyperglycemic unconsciousness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hyperglycaemic unconsciousness</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201008</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood glucose</testname>
				<testresult>412</testresult>
				<testunit>mg/dl</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemic unconsciousness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemic unconsciousness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LEVEMIR</medicinalproduct>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN DETEMIR</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a consumer and forwarded by a <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer</Semaphore>, <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a <Semaphore x="1387834" class="Patient Age" value="59" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="59" score="1.00" ID="">59 </Semaphore>year old </Semaphore>female patient of unknown origin. Additional information was received from the consumer.Medical history was not reported. Concomitant medications included <Semaphore x="730409" class="Medicine" value="insulin detemir" score="0.49" ID="232637"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>detemir </Semaphore>via vial.The patient received <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.87" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>(<Semaphore x="669768" class="Medicine" value="Humalog" score="0.49" ID="228096">Humalog</Semaphore>) for <Semaphore x="2659498" class="Disease or Finding" value="Type 2 Diabetes Mellitus" score="1.00" ID="C26747">Type 2 diabetes mellitus </Semaphore>beginning on an unknown date. <Semaphore x="1863371" class="Procedure" value="Dose Frequency" score="1.00" ID="C89081">Dose and frequency </Semaphore>was not reported. In Aug2010, an unknown time after initiation of <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.87" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro</Semaphore>, the patient <Semaphore x="3073977" class="MedDRA LLT" value="Loss of consciousness" score="1.00" ID="10024855">passed out </Semaphore>for two hours due to <Semaphore x="2036529" class="Disease or Finding" value="Hyperglycemia Artifact" score="1.00" ID="C87037">high blood sugar</Semaphore>. This event was considered serious by the company due to medical <Semaphore x="2521236" class="Disease or Finding" value="Significant Arterial Dissection" score="1.00" ID="C99709">significance</Semaphore>. The patient awoke two hours later with a <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>sugar of 412 mg/dl. The patient drank a lot of <Semaphore x="1361751" class="Medicine" value="Water" score="0.49" ID="196879">water </Semaphore>and recovered. It was reported that the patient did not seek <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>from her <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>and did not <Semaphore x="2032500" class="Disease or Finding" value="Hospitalization Required" score="1.00" ID="C50414">require <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore></Semaphore>. No further information was provided and corrective <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>was not reported. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was recovered; the patient is doing much better and is eating more vegetables, apples, leafy vegetables and everything. On an unknown date <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.87" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>was discontinued.Additional Case(s) for Same Patient: US201210001015Update 22-Jan 2013: Information reported on 01-Oct 2012 to non serious events was previously captured in case US201210001015. Follow up information was received from consumer on 16-Jan 2013. Added date of birth and age. Added indication for suspect product. Updated action taken and updated dechallenge. Added formulation vial for concomitant medication. Updated narrative.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>